Medical/Pharmaceuticals
Trajan Group acquires Neoteryx LLC
MELBOURNE, Australia, Jan. 10, 2022 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has completed the acquisition of Neoteryx, LLC (Neoteryx), a global leader in blood microsampling devices based inTorrance, California,...
2022-01-11 00:00
3418
The new symptoms of the COVID period that CDAHK doctors have uncovered
HONG KONG, Jan. 10, 2022 /PRNewswire/ -- As the COVID-19 Omicron variety continues to spread, chiropractors see a spike in neck pathology from work-from-home, remote learning during pandemic. For 30 years before the COVID-19 pandemic, the majority of chiropractic patients were suffering from bac...
2022-01-10 23:52
2652
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced thatthe United States Food and Drug Administration (FDA)...
2022-01-10 21:50
4005
New Resource from NCCN Shares Evidence-Based Approaches to Recognize and Manage Graft-Versus-Host Disease after Stem Cell Transplantation
PLYMOUTH MEETING, Pa., Jan. 10, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients®: Graft-Versus-Host Disease (GVHD). GVHD is a complication that occurs after a donor stem cell or bone marrow (a.k.a. hematopo...
2022-01-10 21:37
2236
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Everest Medicines
2022-01-10 21:35
5136
Clinical study on Bactiguard's endotracheal tube now published - shows significant reduction of ventilator-associated pneumonia
STOCKHOLM, Jan. 10, 2022 /PRNewswire/ -- The VITAL study, by Professor Pierre Damas and his team, is now published in the well renowned journal Annals of Intensive Care. The study shows a 53% reduction of ventilator-associated pneumonia with Bactiguard's endotracheal tube. It was presented for th...
2022-01-10 20:57
2312
Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma Report also examines key therapeutic development areas to watch including mRNA, CRISPR, AI-driven drug discovery and more LONDON, Jan. 10, 2022 /...
2022-01-10 16:00
3311
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors. AS...
2022-01-10 08:30
4360
SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE
SINGAPORE, Jan. 7, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has appointed Dr.Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis' technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include dev...
2022-01-07 23:00
3790
Healthcare providers can expect to receive US$725 reimbursement from CMS when using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay
FAIRFIELD, N.J., Jan. 7, 2022 /PRNewswire/ -- Vela Diagnostics announced that itsSentosa® SQ HIV-1 Genotyping Assay is covered for reimbursement from The Centers for Medicare and Medicaid (CMS) startingJanuary 2022. Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare...
2022-01-07 22:00
2964
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from10-13 January 2022. The co...
2022-01-07 21:00
5124
100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
TAIPEI, Jan. 7, 2022 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure i...
2022-01-07 18:53
3082
Li Jian Quan, Chairman of WINNER MEDICAL Co., Ltd., Was Invited to "DIALOGUE PROGRAM" in CCTV-2 (China Central Television)
SHENZHEN, China, Jan. 7, 2022 /PRNewswire/ -- On the evening of January 1, Li Jian quan, chairman of Winner Medical, was a guest on "DIALOGUE PROGRAM" in CCTV-2 (China Central Television) as a representative of entrepreneurs. In the interview, he said that only by insisting on innovation can we b...
2022-01-07 17:47
2567
Elekta to appoint Tobias Hägglöv as Chief Financial Officer
STOCKHOLM, Jan. 7, 2022 /PRNewswire/ -- Elekta (STO: EKTA-B) announced today that it will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. Tobias Hägglöv has previously held the role of CFO at Recipharm as well as senior management posit...
2022-01-07 14:49
2807
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
BEIJING, Jan. 7, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company's latest development. Details are as follows: Morgan Stan...
2022-01-07 08:30
2802
Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
HONG KONG and NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference.Alex Zhavoronkov, Founder and Chief Executive Officer of I...
2022-01-07 03:55
2722
LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases
SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based therapeutics, announced that it has executed a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. LISCure has been conducting j...
2022-01-06 22:00
2296
I-Mab Announces Senior Management Team Share Purchase Plan
SHANGHAI and GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the senior management team of the Company, includin...
2022-01-06 21:00
4235
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent ...
2022-01-06 20:30
4178
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 6, 2022 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Cadonilimab (PD-1/CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody), the novel immuno-o...
2022-01-06 19:00
2839
Week's Top Stories
Most Reposted
Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Appier Delivers Record-High Revenue, Profitability and Core Free Cash Flow
[Picked up by 294 media titles]
2026-08-13 23:42Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 294 media titles]
2026-08-10 19:12
Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
16624
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
16398